Dyadic International, Inc. Announces Research and Development Collaboration To Produce An Active Ingredient in C1
GlobeNewswire•February 7, 2018
JUPITER, Fla., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and production of biologic products at commercial scales, today announced that it has entered into a funded proof of concept research collaboration to explore the potential of its C1 technology to produce an important active moiety with an integrated, global biotech company.
“This research & development program will utilize C1’s advanced genetic and metabolic engineering tools as well as its novel characteristics to develop a more rapid and environmentally friendly, lower cost biologic process for the desired primary metabolite which aims to offer an alternative to the current commercial chemical manufacturing process being used by our collaborator. This program offers a terrific opportunity to begin to demonstrate the potential benefits of using our C1 technology to develop and manufacture an additional class of compounds,” said Mark Emalfarb, Dyadic’s CEO.
“In this research collaboration, we will be using state of the art metabolic modeling, synthetic biology and genome engineering techniques to demonstrate the benefits of using C1 as a primary metabolite-producing host organism for producing an active compound,” said Ronen Tchelet, Ph.D., Dyadic’s VP of Research. “Additionally, the knowledge and data generated in this program will enhance our understanding of C1’s metabolic characteristics and help us with more rapidly advancing our ongoing C1 biologic vaccine and drug research and development programs.”
